Table 4.
Characteristics of 160 hepatitis B surface antigen-seropositive cancer patients undergoing cytotoxic chemotherapy n (%)
| Patients developed HBV reactivation (n = 53) | Patients who did not develop HBV reactivation (n = 107) | P value | |
| Sexa | < 0.05 | ||
| Men | 43 (38.4) | 69 (61.6) | |
| Women | 10 (20.8) | 38 (79.2) | |
| Age (yr), median (range) | 51.5 (24.8-78.2) | 52.9 (27.8-77.9) | |
| Tumor typeb | < 0.05 | ||
| Lymphomas | 10 (55.6) | 8 (44.4) | |
| Solid tumor | 43 (30.3) | 99 (69.7) | |
| Liver cancer | 25 (35.7) | 45 (64.3) | |
| Others | 18 (25.0) | 54 (75.0) | |
| ALT levels, median (range) (normal < 58 IU/mL) | 69.1 (21.9-116.3) | 55.7 (18.2-93.2) | |
| HBeAg statusc | < 0.01 | ||
| Positive | 17 (73.9) | 6 (26.1) | |
| Negative | 36 (26.3) | 101 (73.7) | |
| HBV DNA statusd | < 0.01 | ||
| Positive | 47 (45.2) | 57 (54.8) | |
| Negative | 6 (10.7) | 50 (89.3) | |
| Use of rituximab | < 0.05 | ||
| Yes | 6 (60) | 4 (40) | |
| No | 47 (31.3) | 103 (68.7) | |
| Use of corticosteroids | < 0.05 | ||
| Yes | 8 (61.5) | 5 (38.5) | |
| No | 45 (30.6) | 102 (69.4) | |
| Receiving antiviral therapy | < 0.01 | ||
| Yes | 1 (2.1) | 46 (97.9) | |
| No | 52 (46.0) | 61 (54.0) |
a
P = 0.040 (OR: 2.634, 95%CI: 1.046-6.63);
b
P = 0.002 (OR: 5.700, 95%CI: 1.869-17.380);
c
P = 0.000 (OR: 6.064, 95%CI: 2.213-16.621);
d
P = 0.006 (OR: 5.982, 95%CI: 1.689-21.194). OR: Odds ratio; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen.